By Healthcare Dive Staff
Published July 23, 2026
In a strategic move to solidify its position within the rapidly evolving landscape of medical technology, Nabla—a prominent player in the AI-powered clinical documentation sector—has announced the appointment of Brian Manning as its new Chief Executive Officer. Manning, a seasoned executive with an extensive track record in scaling health tech enterprises, succeeds co-founder Alex LeBrun. The leadership transition marks a pivotal moment for the Paris-based firm as it seeks to capture a larger share of the U.S. clinical market and advance its "agentic AI" capabilities.
The Leadership Transition: A Strategic Shift
Brian Manning’s appointment, which became effective immediately upon the announcement on Tuesday, signals a shift in Nabla’s operational focus. While LeBrun provided the technical vision and foundational leadership required to launch the platform, Manning brings the commercial expertise necessary for aggressive enterprise scaling.
Manning’s pedigree is deeply rooted in the American healthcare technology ecosystem. Prior to joining Nabla, he served as the President and Chief Revenue Officer of Bamboo Health, a major player in care coordination and behavioral health analytics. His experience navigating the complexities of healthcare systems—from electronic health record (EHR) integration to state-level controlled substance monitoring—is expected to be instrumental as Nabla attempts to navigate the increasingly crowded AI scribe marketplace.
Alex LeBrun, who has been instrumental in positioning Nabla as a leader in clinical documentation, is not exiting the company entirely. Having taken on the role of CEO at AMI Labs, a frontier AI research firm, earlier this year, LeBrun will transition to the roles of Executive Chairman and Chief AI Officer at Nabla. This arrangement ensures that the company retains its founder’s technical expertise while allowing the new CEO to focus on operational growth and customer acquisition.
Chronology of Growth: From Startup to Series C
Nabla’s ascent in the healthcare sector has been marked by rapid innovation and significant capital infusion. To understand the gravity of this leadership change, one must look at the company’s trajectory:
- Foundation and Early Growth: Established to combat physician burnout, Nabla focused on developing ambient AI scribes capable of listening to patient encounters and drafting high-quality clinical notes.
- Expansion of Partnerships: By 2025, the company had successfully integrated its technology into major health systems, including CVS Health, M Health Fairview, and UCLA Health, building a network of over 190 healthcare organizations.
- 2025 Series C Funding: The company secured a massive $70 million Series C funding round, bringing its total lifetime funding to approximately $120 million. This capital was earmarked specifically for "agentic AI"—systems that do not just transcribe, but proactively assist with clinical decision-making and workflow management.
- 2026 Leadership Pivot: The appointment of Brian Manning in July 2026 marks the beginning of a "scale-up" phase, moving beyond the initial development stage toward becoming a standard utility in clinical settings.
The Competitive Landscape: An AI Arms Race
Nabla is entering a market defined by intense competition. The promise of AI scribes—to return "the gift of time" to clinicians by eliminating the tedious documentation burden—has attracted some of the largest technology firms on the planet.
The field is currently dominated by:
- Big Tech Entrants: Microsoft (via Nuance’s Dragon Ambient eXperience) and Amazon (via AWS HealthScribe) are aggressively embedding AI into the clinical workflow.
- EHR Giants: Epic and Oracle Health have integrated native AI charting tools directly into their platforms, creating a "walled garden" that makes it difficult for third-party AI startups to compete on integration ease.
- Specialized Startups: Beyond Nabla, companies like Abridge and DeepScribe are competing for the same provider dollars, each claiming superior accuracy and workflow seamlessness.
Manning’s background at Zocdoc and PatientPing provides him with a unique perspective on how to compete against these giants. His success in driving revenue at PatientPing prior to its acquisition by Bamboo Health demonstrates an ability to navigate the fragmented U.S. health system, a skill that will be essential for Nabla’s survival.
Supporting Data and Industry Implications
The demand for AI-driven documentation is not merely a trend; it is a response to a systemic crisis. According to recent industry reports, the average physician spends nearly two hours on administrative tasks for every hour of direct patient care. This "pajama time"—the hours spent charting after the clinic has closed—is a primary driver of the current healthcare workforce burnout epidemic.
Nabla’s internal metrics suggest that their AI can reduce documentation time by up to 50% for busy clinicians. However, the industry is also grappling with the "deskilling" concern. Some researchers argue that over-reliance on AI for clinical notes could lead to diagnostic errors or a reduction in the nuanced cognitive process that occurs during manual charting.
Manning enters this environment with a mandate to balance growth with safety. The company’s focus on "agentic AI" suggests they are looking to move beyond simple transcription. Future iterations of their product may include automated order entry, real-time clinical decision support, and proactive patient outreach, all of which require a higher degree of trust and clinical validation than simple scribe tools.
Official Responses and Future Outlook
In a press release issued alongside the announcement, Nabla emphasized that Manning’s appointment is designed to accelerate the deployment of its technology across larger, more complex health systems. "Nabla is at an inflection point," said a spokesperson for the firm. "With our technology proven and our funding secured, the focus now turns to scaling our reach and ensuring that we can support the diverse clinical workflows of our partners."
For his part, Brian Manning noted in internal communications that the opportunity to lead Nabla represents the "convergence of clinical utility and technical possibility." He expressed a desire to continue the company’s focus on physician-centric design, noting that tools that do not reduce the burden on the user will inevitably fail in the long term.
The Road Ahead: Challenges for the New CEO
As Brian Manning settles into the CEO office, he faces three primary challenges:
- Market Saturation: With Epic and Oracle embedding free or low-cost AI tools into their EHRs, Nabla must prove that its third-party solution offers a "value-add" that justifies an additional line item on a hospital’s budget.
- Regulatory Scrutiny: As AI in healthcare moves from "transcription" to "clinical decision support," the level of regulatory oversight from bodies like the FDA will likely increase. Ensuring that the AI remains compliant while continuing to innovate will be a delicate balancing act.
- Interoperability: To succeed in the U.S. market, Nabla must ensure that its data flows seamlessly into the various EHR platforms used by its 190+ partner organizations. Friction in this area is often the death knell for even the most advanced AI tools.
The transition from a founder-led startup to a professionally managed growth company is a hurdle that many promising health tech firms fail to clear. However, with $120 million in backing and a clear, identified need in the clinical market, Nabla appears positioned to remain a formidable competitor. Under Manning’s leadership, the company will likely prioritize "stickiness"—ensuring that once a health system adopts Nabla, the tool becomes as essential as the stethoscope.
As of July 2026, the industry is watching closely. The success of this transition will serve as a bellwether for the broader AI healthcare sector, indicating whether specialized startups can maintain their independence and influence in a world where technology giants are increasingly eager to control the clinical desktop.
